Buy Nitrocor tab. sublingual 0.5mg �40 (in vitro)

Details

Description

Release form, composition and packaging

Sublingual tablets 1 tab.

nitroglycerin 500 mcg

lactose.

40 pcs.

- polymer test tubes (1) - cardboard packs.

pharmachologic effect

Peripheral vasodilator with a predominant effect on the venous vessels.

Antianginal remedy.

The mechanism of action is associated with the release of the active substance nitric oxide in vascular smooth muscle.

Nitric oxide activates guanylate cyclase and increases cGMP levels, which ultimately leads to relaxation of smooth muscle.

Under the influence of glyceryl trinitrate, arterioles and precapillary sphincters relax to a lesser extent than large arteries and veins.

This is partly due to reflex reactions, as well as less intense formation of nitric oxide from active substance molecules in the walls of arterioles.

The action of nitroglycerin (glyceryl trinitrate) is mainly associated with a decrease in myocardial oxygen demand due to a decrease in preload (expansion of peripheral veins and a decrease in blood flow to the right atrium) and afterload (decrease in systemic vascular resistance).

Promotes the redistribution of coronary blood flow to the ischemic subendocardial areas of the myocardium.

Increases exercise tolerance in patients with coronary artery disease, angina pectoris.

In heart failure, it contributes to the unloading of the myocardium, mainly by reducing the preload.

Reduces pressure in the pulmonary circulation.

Pharmacokinetics

After oral administration, it is absorbed from the gastrointestinal tract, undergoes the first pass" effect through the liver.

With sublingual administration, this effect is absent, and the therapeutic concentration in the blood plasma is achieved within a few minutes.

It is metabolized in the liver with the participation of nitrate reductase.

From nitroglycerin metabolites, dinitro derivatives can cause severe vasodilation

perhaps it is they who determine the therapeutic effect of nitroglycerin (glyceryl trinitrate) when taken orally.

Plasma protein binding is 60%.

T1 / 2 after oral administration - 4 hours, with sublingual administration - 20 minutes, after intravenous administration - 1-4 minutes.

It is excreted mainly by the kidneys.

Indications for use

For sublingual and buccal use: relief and prevention of angina attacks

as an ambulance for acute myocardial infarction and acute left ventricular failure at the prehospital stage.

For oral administration: relief and prevention of angina attacks, rehabilitation treatment after myocardial infarction.

For intravenous administration: acute myocardial infarction, incl.

complicated by acute left ventricular failure

unstable angina

pulmonary edema.

For cutaneous use: prevention of angina attacks.

Contraindications for use

Shock, collapse, arterial hypotension (systolic blood pressure < 100 mm Hg, diastolic blood pressure < 60 mm Hg), acute myocardial infarction with severe arterial hypotension, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, cardiac tamponade, toxic pulmonary edema, increased intracranial pressure (including with hemorrhagic stroke, after a recent head injury), angle-closure glaucoma with high intraocular pressure, increased sensitivity to nitrates.

Dosage regimen

Applied sublingually, buccal, inside, skin, intravenous drip.

The dose and treatment regimen are set individually, depending on the indications, the specific clinical situation, and the dosage form used.

Side effect

From the side of the cardiovascular system: dizziness, headache, tachycardia, hyperemia of the skin, a feeling of heat, arterial hypotension

rarely (especially in case of overdose) - collapse, cyanosis.

From the digestive system: nausea, vomiting.

From the side of the central nervous system: rarely (especially in case of an overdose) - anxiety, psychotic reactions.

Allergic reactions: rarely - skin rash,

Name ENG

NITROKOR

Clinical and pharmacological group

Peripheral vasodilator.

Antianginal drug

ATX code

Glyceryl trinitrate

Dosage

500μg

Structure

1 tab.

contains nitroglycerin 0.5 mg

Indications

For sublingual and buccal use: relief and prevention of angina attacks

as an ambulance for acute myocardial infarction and acute left ventricular failure at the prehospital stage.

For oral administration: relief and prevention of angina attacks, rehabilitation treatment after myocardial infarction.

For intravenous administration: acute myocardial infarction, incl.

complicated by acute left ventricular failure

unstable angina

pulmonary edema.

For cutaneous use: prevention of angina attacks.

Storage conditions and periods

At a temperature not higher than 25 degrees (away from fire).

Expiration date: 2 years

Contraindications

Shock, collapse, arterial hypotension (systolic blood pressure < 100 mm Hg, diastolic blood pressure < 60 mm Hg), acute myocardial infarction with severe arterial hypotension, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, cardiac tamponade, toxic pulmonary edema, increased intracranial pressure (including with hemorrhagic stroke, after a recent head injury), angle-closure glaucoma with high intraocular pressure, increased sensitivity to nitrates.

INN / Active ingredient

glyceryl trinitrate (nitroglycerin)

Specifications